D J Booser
Overview
Explore the profile of D J Booser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bayraktar S, Gutierrez-Barrera A, Lin H, Elsayegh N, Tasbas T, Litton J, et al.
Clin Exp Metastasis
. 2013 Feb;
30(5):631-42.
PMID: 23370825
The aim of this study was to compare the time-to progression and overall survival (OS) in patients with metastatic breast cancer (MBC) with and without deleterious BRCA1/2 mutations. 195 women...
2.
Cristofanilli M, Morandi P, Krishnamurthy S, Reuben J, Lee B, Francis D, et al.
Ann Oncol
. 2008 Jun;
19(10):1713-9.
PMID: 18515258
Background: Novel molecular therapies for metastatic breast cancer (MBC) are necessary to improve the dismal prognosis of this condition. Imatinib mesylate (Gleevec) inhibits several protein tyrosine kinases, including platelet-derived growth...
3.
Yang C, Gonzalez-Angulo A, Reuben J, Booser D, Pusztai L, Krishnamurthy S, et al.
Ann Oncol
. 2006 Jan;
17(5):813-7.
PMID: 16403809
Background: Bortezomib (VELCADE) is a potent inhibitor of the 26S proteasome with broad antitumor activity. We performed a phase II study of bortezomib to evaluate its clinical effects in patients...
4.
Ibrahim N, Valero V, Rahman Z, Theriault R, Walters R, Buzdar A, et al.
Cancer Invest
. 2001 Jul;
19(5):459-66.
PMID: 11458813
Vinorelbine (Navelbine) has significant activity against breast carcinoma and is less neurotoxic than vinblastine. Because vinblastine has improved activity when administered by continuous infusion, we conducted a Phase I-II study...
5.
Brito R, Valero V, Buzdar A, Booser D, Ames F, Strom E, et al.
J Clin Oncol
. 2001 Feb;
19(3):628-33.
PMID: 11157012
Purpose: To determine outcomes in local-regional control, disease-free survival, and overall survival in patients with locally advanced breast cancer (LABC) who present with ipsilateral supraclavicular metastases and who are treated...
6.
Booser D, Perez-Soler R, Cossum P, Wu Q, Zou Y, Priebe W, et al.
Cancer Chemother Pharmacol
. 2000 Dec;
46(5):427-32.
PMID: 11127949
Annamycin is a highly lipophilic anthracycline with the ability to bypass the MDR-1 mechanism of cellular drug resistance. In this phase I study, annamycin entrapped in liposomes was administered by...
7.
Ibrahim N, Valero V, Theriault R, Willey J, Walters R, Buzdar A, et al.
Am J Clin Oncol
. 2000 Apr;
23(2):117-21.
PMID: 10776969
The purpose of this study was to evaluate the maximum tolerated dose and the toxicity profile of vinorelbine administered by continuous infusion for 96 hours to patients who had received...
8.
Booser D, Walters R, Holmes F, Hortobagyi G
Am J Clin Oncol
. 2000 Feb;
23(1):40-1.
PMID: 10683074
Twelve women with metastatic breast cancer were treated with continuous infusion high dose leucovorin, 5-fluorouracil and cisplatin. Toxicity was severe although the dose was lower than previously described for the...
9.
Hortobagyi G, Buzdar A, Theriault R, Valero V, Frye D, Booser D, et al.
J Natl Cancer Inst
. 2000 Feb;
92(3):225-33.
PMID: 10655439
Background: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial...
10.
Buzdar A, Singletary S, Theriault R, Booser D, Valero V, Ibrahim N, et al.
J Clin Oncol
. 1999 Nov;
17(11):3412-7.
PMID: 10550135
Purpose: To compare prospectively the antitumor activity of single-agent paclitaxel to the three-drug combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer. Patients...